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Summary
Interleukin 1(IIA) is an endogenously produced cytokine that mediates a variety ofphysiological
effects that may be beneficial or deleterious to the host . C57B1/6 mice treated intravenously
with a recently characterized human recombinant receptor antagonist protein to IL1 (IIrlra)
had improved survival when treated after a lethal Escherichia coli endotoxin (lipopolysaccharide
[LPS]) challenge. IIrIra was effective when treatment was initiated after LPS, and intravenous
administration every 4 h for 24 h was required . Serum levels of tumor necrosis factor (TNF)
activity afterLPS and in vitroTNF cytotoxicity were not altered by treatment with ILL1ra . These
experiments provide direct evidence that the lethal effects ofLPS may be mediated through the
action ofILI and that the IIr1ra can provide anew treatment strategy for diseaseprocesses mediated
via this cytokine.
R
ecent evidence suggests that the administration of endo-
toxin or bacteremia initiates the production and release
ofendogenouslyproduced cytokines such asTNF, ILI, IL6,
and IFN--y in a complex cascade through which the lethal
effects of endotoxin or septicemia are mediated . The role of
TNF as a central mediator of the lethal effects of endotoxin
has been supported by the findings that : (a) infusion ofTNF
causes shock, tissue injury, and death characteristic of endo-
toxin shock ; (b) passive immunization against TNF protects
mice from a subsequent lethal endotoxin challenge and pre-
vents hypotension during lethal bacteremia in the baboon ;
and (c) circulating plasmaTNF levels peak very rapidly after
endotoxin administration (1-3) . However, after the adminis-
tration of a lethal endotoxin challenge in mice, death typi-
cally occurs from 24 to 48 h later, during which time the
deleterious effects of a variety of endogenous mediators may
be contributing to the demise of the animal .
We hypothesized that since ILI shares many physiological
activities with TNF and is produced and released in large
quantities soon after TNF in response to endotoxin or bac-
teremia (4-7), it may also be a central comediator of endo-
toxin lethality . The repetitive administration of ILI, in
amounts comparable with physiologically produced concen-
trations, causes anorexia, inflammation, and fever (8-10), while
higher doses induce hypotension, tissue injury, organ failure,
and death characteristic ofseptic shock (11, 12) . ILI andTNF
act synergistically to enhance lethality when both cytokines
are given in sublethal doses in vivo (13) . A treatment strategy
directed towards inhibiting the deleterious physiological effects
of IL1 may ameliorate or prevent tissue injury or death in
inflammatory or infectious disease states.
Recently, a newly described receptor antagonist to IIr1(II.,
Ira) produced from IgG-adherent human monocytes has been
purified, sequenced, and cDNA for the 18-kD protein ex-
pressed in Escherichia coli (14, 15) . The protein binds to the
ILI receptor but has no agonist activity, nor does it bind
to the cytokine. The current experiments were performed
to determine the in vivo effects ofthe Ilrlra against the lethality
of endotoxin .
Materials and Methods
Animals .
￿
Female C57B1/6 mice weighing 19-21 g were housed
six per cage and kept in a controlled environment . All experiments
were conductedin compliance with the Animal Care and Use Com-
mittee of the National Institutes of Health .
Reagents.
￿
IIAra (generously supplied byR.C . Thompson, Syn-
ergen, Inc., Boulder, CO) was brought to a final concentration
in 0.5% fatty acid-poor endotoxin-free BSA (Calbiochem-Behring
Corp ., La Jolla, CA) and kept at 2-8°C . Control mice received
an equal volume of protein carrier solution (vehicle) . E. coli endo-
toxin (LPS, serotype 0127:B8) was purchased from Sigma Chem-
ical Co. (St . Louis, MO) and reconstituted in saline to a standard
concentration of 10 cc/kg.
In Vitro IL1ra Activity.
￿
Thymocytes from 6-wk-old C3H/HeJ
mice were incubated for 72 h with recombinant human (rh)IIr2
(Cetus Corp., Emeryville, CA) and, where indicated, 100,000 U/ml
rhIIrltx (Hoffman-La Roche, Inc ., Nutley, NJ) as described for the
mouse thymocyte assay (16) ; 106 cells were placed in each well
with 200 jl complete media (RPMI with 10% FCS) . IIr1ra was
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1029-1032included in the media in serial dilutions in the inner 60 wells of
a 96-well plate. [3H]Thymidine was added to the media after 72 h
(1 ACi per well) and incubatedfor6 h. Cells were then harvested
onto glass fiber filters and [3H]thymidine uptake was measured in
a Betaplateliquid scintillation counter (Pharmacia/LKB Biotech-
nology, Inc., Piscataway, NJ).
Aconfluentmonolayer of L929 cells in each oftheinner60 wells
of 96-well plates was incubated for 18 h with 200 Ntl of complete
media containing dactinomycin (1.36 ttg/ml) as well as rmuTNF
(Genentech, Inc., South San Francisco, CA) andI1r1ra in the con-
centrations indicated, in a fashion similar to thoe L929 bioassay
forTNF (17). Thecellswere washed, fixed, andstainedwith crystal
violet; retained dye was solubilized; and absorbance (595 nm) was
measured on aTitertek Multiscan platereader (FlowLaboratories,
McLean, VA).
In Vivo Circulating TNFActivity.
￿
Mice (n = 29) were treated
with either IL1ra (25 mg/kg) or vehicle intravenously followed
by LPS (30 mg/kg) intravenously 10 min later. Mice were exsan-
guinated by retro-orbital puncture 90 min and 4h afterLPS. Serum
was separated and frozen at -20°C until analyzed. TNF activity
was analyzed by the L929 assay as described. Units of TNF were
calculated as the reciprocal of the serum dilutions at half killing
as determined by log transformation and linear regression analysis
of dilutions vs. absorbance. All activity was blocked by a specific
rabbit anti-mouse TNF antibody purified in ourlaboratory (18).
Survival Experiments.
￿
Allsurvival experiments followed thesame
general format. In each experiment, mice were injected in-
traperitoneally with 40 mg/kgE. coli LPS.After20 min, mice were
n
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randomly assigned (12/group) to receive IL1ra or an equalvolume
of vehicle every 4-5 h for five doses intravenously. Survival was
assessed every 6 h for 48 h and then daily for6 d. Mice surviving
72 h appeared stable. To assess the effect of duration of treatment
after LPS, mice (11-12/group) were randomized into one of three
treatment groups: (a) ILlra (25 mg/kg) intravenously every 4 h
for five doses; (b) ILlra (25 mg/kg) intravenously every 4 h for
two doses followed by vehicle for three doses; or (c) an identical
volume of vehicle intravenously every 4 h for five doses.
Statistics.
￿
Survival curves were constructed by theKaplan-Meer
method andanalyzed fordifferences usingthe score test of the Cox
proportional hazards model for grouped data. The in vitro effects
ofincreasing concentrations of ILlrawere tested usinglinearregres-
sion on thebase 10 logarithmof the concentrations, with analysis
of the residuals for normality andfor absence ofothertrends. Other
data were evaluated using Student's t test with unknown but as-
sumed equal variance.
Results and Discussion
Initial in vitro experiments demonstrate that the IIAra in-
hibits the proliferation of ILl-dependent C3H/HeJ mouse
thymocytes in a dose-dependent fashion and has no biologi-
cally significant effect on TNF cytotoxicity againstL929 cells
(Fig. 1). In the mouse thymocyte experiment (Fig. 1 A), the
slope of the regression line for data points with ILl is
significantly different from control (p <0.0001) . In theL929
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Figure 1.
￿
In vitro activity of the II,
Ira. (A)Theaddition of increasing doses
oftheILlrainhibits thecellular prolifer-
ation ([3H]-thymidine uptake) induced
by theaddition of II.A. Cells exposed
to 11,2 alone maintain a low level of
[3H]thymidine uptake, and the IL1ra
does notinhibit ID2 activity. Each data
pointrepresents threeseparate wellsin-
cubated concurrently. (B) Increasing
concentrations oftheILlradoes notin-
hibit cellular cytotoxicity inducedby in-
creasing concentrations of rhTNF. Each
data pointrepresents threeconcurrently
run experiments.
Figure 2.
￿
(A) Survival after adminis-
tration ofLPSin mice treated with IL
Iraor vehicle.Either IL1ra(25 mg/kg)
or vehicle was administered intrave-
nously as described. Mice treated with
ILlrabeginning20 minafter adminis-
tration of LPS had significantly im-
proved survival compared with vehicle-
treated controls (p = 0.004). (B)Effect
of duration oftreatment with IL1raon
survival after LPSin mice. After LPS,
micewere randomized into oneof three
treatment groups as described in Ma-
terialsandMethods. Mice treated every
4 h with five doses of IL1ra had sig-
nificantly better survival than mice
treated with either two doses of ILlra
or vehicle (p = 0.01). Twodoses of IL
Iradidnotimprovesurvival compared
with vehicle alone.Table 1.
￿
Effect ofIL-Ira on Circulating Levels of TNF Activity
After LPS
Figures in parentheses are n.
t NS vs. IL-Ira at each time point.
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experiment (Fig. 1 B), the slope of the regression lines with
varying doses of TNF are negative and, at TNF concentra-
tions of 0.05 and 0.2 ng/ml, are significantly different from
the other three. This does not represent, however, biologi-
cally important alterations in cell killing and does not show
any inhibition of TNF cytotoxicity at any IIx1ra concentration.
In the in vivo experiments, female C57B1/6 mice were in-
jected intraperitoneally with 40 mg/kg ofLPS; 20 min later,
treatment with either IIr1ra or an equal volume of carrier
solution was instituted every 4 h for 24 h. In this animal
model, others have demonstrated that the receptor antagonist
blocks IL-1-induced IL-6 production for up to 6 h, indicating
that in its present formulation interval injections are neces-
sary for a prolonged effect (W.R. Benjamin, personal com-
munication) . In initial experiments, doses between 5 to 25
mg/kg were not effective in improving survival when the
IL1ra was administered subcutaneously (data not shown). Mice
treated with the IL1ra (25 mg/kg) intravenously had a
significantly improved survival compared with control animals
(Fig. 2 A). When the dose of ILlra was doubled a similar
survival was noted, implying that the lower dose had effec-
tively blocked receptor sites on target cells and that a higher
dose of receptor antagonist protein did not have any addi-
tional therapeutic value (data not shown). The receptor an-
tagonist was not effective in improving survival after LPS
when administered intravenously for only two rather than
five doses (Fig. 2 B). After the administration ofLPS, animals
treated with IL1ra appeared to have less piloerection and fe-
brile shaking than animals treated with vehicle, suggesting
that these were IIA-mediated effects that had been effectively
ameliorated.
To test whether the beneficial effects of II,1ra are secondary
to an alteration of TNF production after LPS, serum levels
ofTNF activity after an intravenous dose ofLPS (30 mg/kg)
were measured in mice treated simultaneously with IL1ra
or vehicle. At either 1.5 or 4 h after LPS, circulating levels
of TNF activity were not altered by treatment with IL1ra,
indicating that the receptor antagonist protein did not exert
its beneficial effects on the lethality of LPS by reducing cir-
culating levels of TNF (Table 1).
The precise timing of IIr1ra treatment necessary to im-
prove survival after LPS has not been determined in these
experiments. It is possible that treatment with ILIra may
be delayed for several hours after LPS as serum levels of IL1
do not peak until approximately 3-5 h after LPS (7). While
circulating levels of ILl after endotoxin are measurable for
as long as 8 h (6, 7), physiologically active IL1 may be present
in tissues for hours or days. In this animal model, treatment
for >8 h was necessary for a survival advantage.
The most significant feature of IL1ra protection against
LPS lethality is the fact that it is effective when treatment
is initiated after the administration of endotoxin. Previous
attempts to improve survival against LPS lethality using agents
that either block the productionor activity of endogenously
produced mediators have only been effective when the agent
was administered before LPS (19). For example, passive im-
munization against TNF improves survival against lethal en-
dotoxemia when antibody is given 6 h before LPS (2). Treat-
ment with anti TNF antibody simultaneously or after LPS
may not allow time for circulation and dispersion of the an-
tibody into host tissues to counter the rapid deleterious effects
of TNF. However, the deleterious effects of IIL1 may be of
slower onset and more protracted, which may explain why
treatment with Ilr1ra can be initiated after the administra-
tion ofLPS and is not effective when given for only two doses.
In conclusion, these experiments demonstrate that IIL1 is
a central mediator in endotoxin lethality. Furthermore, an
antagonist to the receptor for IIr1 can be used in vivo as an
effective treatment strategy to improve survival after lethal
endotoxemia in mice. A receptor antagonist to ILl may be
a clinically applicable treatment strategy in disease processes
mediated by this cytokine in humans.
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